A model-based analysis suggests that coformulation of semaglutide with SNAC does not alter the pharmacokinetics of semaglutide once absorbed, with oral and subcutaneous formulations of semaglutide distributed, metabolized, and eliminated in the same way (42)
Wegovy clinical studies and reported hair loss percentages Wegovy clinical trials show more notable results: Hair loss affected 3% of adult participants compared to 1% in the placebo group [7] The numbers were higher in children 12 and older, where 4% reported hair loss while the placebo group showed no cases [8] Comparing hair loss rates across different GLP-1 medications GLP-1 medications of all types show distinct patterns: Tirzepatide (Mounjaro): Users reported hair loss rates between 4.9% to 5.7% at doses from 5mg to 15mg [8] Zepbound: The overall rates reached 4% to 5%, with women showing much higher numbers 7.1% compared to just 0.5% in men [8] Research from the University of British Columbia shows that people who use semaglutide have a 52% higher chance of hair loss compared to those taking older weight loss medications [9]
Who Should Be Cautious With GLP-1 Medications
Reasonable markers to track: waist circumference, weight, resting heart rate, sleep quality, and a basic liver panel (ALT, AST) before and after long cycles
These include medical expenses, lost wages, pain and suffering, emotional distress, and potentially punitive damages if deemed necessary by a judge or jury
